Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v29.i2.10
pages 89-148

Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer

Vivek Ranjan Sinha
Pharmaceutics Division, University Institute of Pharmaceutical Sciences, (UGC-Centre of Advanced Study), Panjab University, Chandigarh-160014, India
Honey
Pharmaceutics Division, University Institute of Pharmaceutical Sciences, (UGC-Centre of Advanced Study), Panjab University, Chandigarh-160014, India

ABSTRACT

The strategic goal behind adjuvant therapy is to open novel avenues for colon cancer treatment by specifically inactivating pathways needed for the growth of tumor cells. 5-Fluorouracil (5-FU) therapy is a prominent conventional treatment for colon cancer that has been used for five decades. Among the rich diversity of chemotherapeutics, 5-FU has been extensively manipulated as an anticancer drug. The pharmacology of 5-FU has spawned myriad alternatives to achieve low-toxicity treatment for better colon cancer management. The existing highly toxic chemotherapeutic regimens, lack of new congeners with significant efficacy, and drug resistance to cancer cells have prompted scientists to manipulate conventional treatments. These factors make it imperative to rationalize the current 5-FU therapy in combination with synthetic or natural compounds by optimizing the dose with respect to pharmaco-kinetic and preclinical data. To attempt to tailor effective conventional 5-FU regimens, novel therapeutic perspectives associated with the 5-FU-based colon cancer chemotherapy currently available in clinical settings have been summarized. This review presents comprehensive summary of a dedicated literature search of databases (i.e., PUBMED, CAPLUS, and MEDLINE) for adjuvant approaches such as NSAIDs (COX-II inhibitors), natural compounds, viral vectors, novel agents/molecules, and various targeted therapies, in combination with 5-FU in developing treatment alternatives for colon cancer.


Articles with similar content:

Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 5
Huanchen Sha, Fuguo Xu, Qingyong Ma
siRNA: A Potential Tool for Future Breast Cancer Therapy?
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 1-2
Eirik Frengen, Tone Ikdahl Andersen, Charles M. Perou, Gro Leite Storvold
Stealth Engineering for In Vivo Drug Delivery Systems
Critical Reviews™ in Biomedical Engineering, Vol.43, 2015, issue 5-6
Ankita Mohapatra, Richard A. Smith, Bashir I. Morshed, Warren O. Haggard
Critical Review on Curcumin as a Therapeutic Agent: From Traditional Herbal Medicine to an Ideal Therapeutic Agent
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 1
Muhammad Ibrahim, Muhammad Imran Qadir, Muhammad Sajid Hamid Akash, Kanwal Rehman, Muhammad Usman Akbar, Khalid Mahmood Zia
Drug Combinations with HDAC Inhibitors in Antitumor Therapy
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Noemi Arrighetti, Cristina Corno, Laura Gatti